1. Home
  2. ERAS vs CIVB Comparison

ERAS vs CIVB Comparison

Compare ERAS & CIVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • CIVB
  • Stock Information
  • Founded
  • ERAS 2018
  • CIVB 1884
  • Country
  • ERAS United States
  • CIVB United States
  • Employees
  • ERAS N/A
  • CIVB N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • CIVB Major Banks
  • Sector
  • ERAS Health Care
  • CIVB Finance
  • Exchange
  • ERAS Nasdaq
  • CIVB Nasdaq
  • Market Cap
  • ERAS 439.7M
  • CIVB 402.3M
  • IPO Year
  • ERAS 2021
  • CIVB N/A
  • Fundamental
  • Price
  • ERAS $2.32
  • CIVB $20.65
  • Analyst Decision
  • ERAS Buy
  • CIVB Buy
  • Analyst Count
  • ERAS 6
  • CIVB 5
  • Target Price
  • ERAS $3.83
  • CIVB $25.50
  • AVG Volume (30 Days)
  • ERAS 1.7M
  • CIVB 109.2K
  • Earning Date
  • ERAS 11-11-2025
  • CIVB 10-23-2025
  • Dividend Yield
  • ERAS N/A
  • CIVB 3.27%
  • EPS Growth
  • ERAS N/A
  • CIVB 18.46
  • EPS
  • ERAS N/A
  • CIVB 2.52
  • Revenue
  • ERAS N/A
  • CIVB $157,428,000.00
  • Revenue This Year
  • ERAS N/A
  • CIVB $17.30
  • Revenue Next Year
  • ERAS N/A
  • CIVB $12.90
  • P/E Ratio
  • ERAS N/A
  • CIVB $8.24
  • Revenue Growth
  • ERAS N/A
  • CIVB 7.00
  • 52 Week Low
  • ERAS $1.01
  • CIVB $17.00
  • 52 Week High
  • ERAS $3.31
  • CIVB $25.59
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 68.53
  • CIVB 51.18
  • Support Level
  • ERAS $1.78
  • CIVB $19.87
  • Resistance Level
  • ERAS $2.65
  • CIVB $20.89
  • Average True Range (ATR)
  • ERAS 0.20
  • CIVB 0.46
  • MACD
  • ERAS 0.05
  • CIVB -0.03
  • Stochastic Oscillator
  • ERAS 68.34
  • CIVB 54.00

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About CIVB Civista Bancshares Inc.

Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agriculture, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. Majority of its revenues are derived from the interest and fees gained on loans.

Share on Social Networks: